skip to search skip to navigation skip to main content


For all general enquiries, please call the Astellas Pharma EMEA switchboard on:

Tel:  +44 (0)203 379 8000.

For journalists and media professionals, please call the switchboard on +44 (0)203 379 8000  and request to speak to a member of the Corporate Communications team or contact us by e-mail using the contact form provided, please marking ‘media’ as the nature of your enquiry.

For all other country specific enquiries, please visit our locations page and contact the relevant Astellas office.

Press releases


World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
14th October 2016
Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business
04th April 2016
Astellas Pharma Europe Ltd. Announces New President of EMEA Operations
04th March 2016


How five 15-year olds from Sussex created an antidote to the ‘share everything’ social media culture
21st October 2015
Half of young people are going online to cope with stress, survey shows
21st October 2015
Astellas Pharma EMEA appoints Eugene Van Rensburg as Chief Financial Officer
16th September 2015
Over 550 women’s lives transformed to‐date with Action on Fistula
28th August 2015
European experts reveal new survey data that demonstrates a need for increased focus on ‘the man behind the prostate cancer’
22nd May 2015
Astellas Pharma EMEA celebrates its 10th anniversary
20th May 2015
Two thirds of Britons would have genetic test to identify risk of disease if it were free on the NHS
06th February 2015
Screen time, not face time
06th February 2015
Technology will enable healthcare to focus on wellness rather than illness, US bio-entrepreneur Dr Leroy Hood to tell The Astellas Innovation Debate™
06th February 2015


Personalised Healthcare: Panacea or Pandora’s Box?
12th December 2014
Phase 3 Prevail Trial Named Clinical Advance of the Year by SCRIP
10th December 2014
Astellas Named on FTSE4Good Index for the Third Year
09th December 2014
XTANDI™ (Enzalutamide) Now Approved in Europe for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer who are Chemotherapy-Naïve
02nd December 2014
UK’s Most Innovative School Students Awarded for Mobile Health App Ideas to Boost Healthy Living
26th November 2014
CHANGING TOMORROW™ Day 2014 Marks Astellas’ Fifth Year of Volunteering
04th November 2014

Privacy Policy  |  Terms of Use Copyright © 2016 Astellas Pharma Europe Ltd
APEL/14/0014/EU January 2015